Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $10.60 | 39,295 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 98 | $10.64 | 39,197 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 2 | $10.66 | 39,195 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 800 | $10.70 | 38,395 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $10.71 | 38,295 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 100 | $10.73 | 38,195 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 400 | $10.74 | 37,795 | |
| May 01, 2008 | Director, President and CEO | Open market or private sale of non-derivative or derivative security | Form 4 | 400 | $10.88 | 37,395 | |
| May 01, 2008 | Chief Financial Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 220 | $10.81 | 35,815 | |
| Apr 24, 2008 | Senior VP, Drug Development | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | $0.64 | 62,116 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.